bioRxiv · 10.1101/2021.01.04.425177
The engineered peptide construct NCAM1-Aβ inhibits aggregation of the human prion protein (PrP)
Abstract
In prion diseases, the prion protein (PrP) becomes misfolded and forms fibrillar aggregates, which are resistant to proteinase degradation and become responsible for prion infectivity and pathology. So far, no drug or treatment procedures have been approved for prion disease treatment. We have previously shown that engineered cell-penetrating peptide constructs can reduce the amount of prion aggregates in infected cells. The molecular mechanisms underlying this effect are however unknown. Here, we use atomic force microscopy (AFM) imaging to show that the aggregation of the human PrP protein can be inhibited by equimolar amounts of the 25 residues long engineered peptide construct NCAM1-A{beta}.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Gielnik, M., Zhukova, L., Zhukov, I., Graslund, A., Kozak, M., Warmlander, S. K. T. S.. 2021-01-04. The engineered peptide construct NCAM1-Aβ inhibits aggregation of the human prion protein (PrP). https://doi.org/10.1101/2021.01.04.425177
Cite the original work for its findings. Save a collection to share your selection of sources.